DEERFIELD, Ill., August 31, 2009 – Chicago-based Lundbeck Inc. was recently recognized with the Award of Excellence in Corporate Achievement by the Illinois Chapter of the Huntington’s Disease Society of America (HDSA) for the company’s significant contributions to the Huntington’s disease (HD) community and making a meaningful contribution to the lives of people in the state of Illinois. The award was presented this past Friday at the fifth annual Celebration of Hope Dinner, chaired by Mayor Richard M. Daley, at the Renaissance Chicago Hotel.

“Lundbeck is committed to providing important resources and support for patients with Huntington’s disease, their families and healthcare professionals in Illinois, and we’re honored to receive the Award of Excellence in Corporate Achievement in recognition of our work,” said Sean Nolan, Lundbeck Inc. Chief Commercial Officer. “For each and every one of us at Lundbeck, this award validates the importance of our work and signals the progress we are making towards our mission of improving the lives of people suffering from complex central nervous system disorders and rare diseases.”

The Celebration of Hope gala celebrates the accomplishments of various community leaders who have made significant contributions in the areas of science, arts, philanthropy and business, as well as those who demonstrate courage and hope in the conduct of their personal and professional lives. The dinner benefits the HDSA Center of Excellence at Rush Medical Center in Chicago. The Center, one of 16 in the United States, provides people with HD and their caregivers with a variety of services to help manage their disease, including clinical care, social work, education, research, speech and occupational therapies and psychiatric care.

“When it came to selecting our corporate Award of Excellence recipient for this year, our planning committee and Board of Directors were unanimous in endorsing the nomination for Lundbeck,” said Blanca Hernandez-McCarthy, Regional Manager of Special Events & Fundraising for HDSA Illinois. “We are of course thrilled that the company offers the first FDA-approved treatment for chorea associated with HD, but beyond that, we have been extremely impressed with their commitment to the many families in Illinois affected with this devastating disease through financial patient support programs and comprehensive educational programs, as well as their overall support of HDSA activities throughout the state.”

About Huntington’s Disease
Huntington’s disease is a neurodegenerative disease that results in uncontrolled movements, emotional disturbances, and mental deterioration. HD is characterized by a combination of motor, cognitive, and psychiatric symptoms that evolve over many years. The average survival time after diagnosis of the illness is 15 to 20 years but can range from 10 to 30 years. Currently, there is no known cure for HD and the disease is ultimately fatal. For more information on HD, please visit www.hdsa.org.

About Lundbeck Inc.
Lundbeck Inc. was established in March 2009 following the acquisition of Ovation Pharmaceuticals, Inc. by Lundbeck and has proven success in developing and commercializing high-need treatments. The company is committed to providing innovative therapies that fulfill unmet medical needs of people with CNS disorders and rare diseases for which few, if any, effective treatments are available. For more information, please visit www.lundbeckinc.com.

About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improve the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose Lundbeck is engaged in the research and development, production, marketing and sale of pharmaceuticals across the world, targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, Alzheimer’s and Parkinson’s diseases. Lundbeck was founded in 1915 by Hans
Lundbeck in Copenhagen, Denmark, and employs today over 5,500 people worldwide. Lundbeck is one of the world’s leading pharmaceutical companies working with CNS disorders. In 2008, the company’s revenue was DKK 11.3 billion (approximately EUR 1.5 billion or USD 2.2 billion). For more information, please visit www.lundbeck.com.

**Lundbeck Media Contact**
Clarissa Vandersteen-Trujillo
Phone: 847-282-1161
cuj@lundbeck.com

**SOURCES**
1. MayoClinic.com Web site: Huntington’s Disease
   Mayoclinic.com/print/huntingtonsdisease/DS00401/DSECTION=all&METHOD=print
